Objective: The current study aimed to investigate the potential of Solid Self-Emulsifying Drug Delivery Systems (solid SEDDS) loaded with Testosterone Undecanoate (TU) (solid TUSEDDS). The solid TU-SEDDS was composed of TU, Medium-Chain Triglycerides (MCT, oil), 2- Chloro-1-(chloromethyl) ethyl carbamate (EL-35, surfactant) and polyethylene glycol (PEG400, cosurfactant). It was expected to improve the dissolution and oral bioavailability of TU, as a result of investigating the feasibility of the clinical application of SEDDS.
Methods: First, a TU-SEDDS was developed by using rational blends of components with the good solubilizing ability for TU. Next, a ternary phase diagram was constructed to determine the self-emulsifying region, and the formulation was optimized. Then, the solid TU-SEDDS formulation was established by screening suitable solid adsorptions. Finally, the prepared SEDDS, TUSEDDS and solid TU-SEDDS formulations were evaluated in vitro and in vivo.
Results: The size of the solid TU-SEDDS was 189.1 ± 0.23 nm. The Transmission Electron Microscopy (TEM) results showed that the oil droplets were homogenous and spherical with good integrity. The Differential Scanning Calorimetry (DSC) and X-Ray Powder Dffraction (XRD) results indicated that the solid TU-SEDDS formulation almost preserves the amorphous state. Scanning Electron Microscopy (SEM) indicated that neusilin US2 successfully adsorbed the TU-SEDDS. Drug release indicated that the dissolution of the solid TU-SEDDS was faster than that of Andriol Testocaps ®. Furthermore, in vivo pharmacokinetic (PK) studies in Sprague-Dawley (SD) rats showed that the Area Under the Curve (AUC) of the solid TU-SEDDS (487.54±208.80 μg/L×h) was higher than that of Andriol Testocaps® (418.93±273.52 μg/L×h, P < 0.05). In beagles not fed a high-fat diet, the AUC of the solid TU-SEDDS (5.81±4.03 μg/L×h) was higher than that of Andriol Testocaps ® (5.53±3.43 μg/L×h, P > 0.05). In beagles fed a high-fat diet, the AUC of the solid TUSEDDS (38.18±21.90 μg/L×h) was higher than that of Andriol Testocaps® (37.17±13.79 μg/L×h, P > 0.05).
Conclusion: According to the results of this research, oral solid TU-SEDDS is expected to be another alternative delivery system for the late-onset hypogonadism. This is beneficial to the transformation of existing drug delivery systems into preclinical and clinical studies.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.2015010159] [PMID: 25955882]
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.2014008502] [PMID: 24940626]
[http://dx.doi.org/10.1016/j.ijpharm.2004.07.046] [PMID: 15707735]
[http://dx.doi.org/10.2174/1567201811666140716122644] [PMID: 25030115]
[http://dx.doi.org/10.1208/s12249-015-0469-8] [PMID: 26694058]
[http://dx.doi.org/10.2164/jandrol.111.013169] [PMID: 21474786]
[http://dx.doi.org/10.1124/jpet.103.052522] [PMID: 12807999]
[http://dx.doi.org/10.1016/j.colsurfb.2012.06.031] [PMID: 23010049]
[http://dx.doi.org/10.1016/j.ejps.2015.03.024] [PMID: 25845633]
[http://dx.doi.org/10.1016/j.xphs.2016.06.019] [PMID: 27492963]
[http://dx.doi.org/10.3109/10717544.2014.898109] [PMID: 24670090]
[http://dx.doi.org/10.1055/a-0573-9132] [PMID: 29589341]
[http://dx.doi.org/10.1111/jphp.12286] [PMID: 24961657]
[http://dx.doi.org/10.1208/s12249-018-1067-3] [PMID: 29845504]
[http://dx.doi.org/10.1016/j.ijpharm.2014.03.040] [PMID: 24657287]
[http://dx.doi.org/10.1016/j.freeradbiomed.2013.05.041] [PMID: 23792276]
[http://dx.doi.org/10.1016/j.ejps.2013.09.023] [PMID: 24157543]
[http://dx.doi.org/10.1016/j.ejpb.2009.03.001] [PMID: 19298857]
[http://dx.doi.org/10.1016/j.colsurfb.2016.02.013] [PMID: 26896653]
[http://dx.doi.org/10.1111/j.1365-2265.2007.02781.x] [PMID: 17371478]